PlainPharmaWatch

CMS Open Payments · Program Year 2024

Novartis Gene Therapies, Inc. (fka Avexis, Inc.)

Novartis Gene Therapies, Inc. (fka Avexis, Inc.) reported $120,016.16 in payments to 15 physicians and teaching hospitals across 39 transactions.

See the rankings → How this is sourced
$120.0K
Total payments
39
Transactions
15
Recipients
−$154.6K
General Payments vs PY2023

Novartis Gene Therapies, Inc. (fka Avexis, Inc.) reported $120,016.16 in payments to 15 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #1136 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $8.0K per recipient across 3 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Novartis Gene Therapies, Inc. (fka Avexis, Inc.) pairs below-median payment volume with a concentrated payment pattern focused on a handful of top recipients.

#1136
of 1,925 companies
0.0%
of all US industry payments
0.6%
paid to its single top recipient
3
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Novartis Gene Therapies, Inc. (fka Avexis, Inc.)'s CMS-reported General Payments decreased by $154.6K (−68.2%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: NOVARTIS GENE THERAPIES, INC. (FKA AVEXIS, INC.)PY2023: NOVARTIS GENE THERAPIES, INC. (FKA AVEXIS, INC.)PY2024: Novartis Gene Therapies, Inc. (fka Avexis, Inc.). Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$226.8KPY2024$72.2K
PY2023
$226,815.35
PY2024
$72,166.50

How Novartis Gene Therapies, Inc. (fka Avexis, Inc.) ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Novartis Gene Therapies, Inc. (fka Avexis, Inc.)'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$120,016 41st percentile higher than 41% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). This entry sits in this band. $242,294–$752,621: 270 reporting companies (14%). Above this entry. $752,621–$2,337,813: 263 reporting companies (14%). Above this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Novartis Gene Therapies, Inc. (fka Avexis, Inc.)

Novartis Gene Therapies, Inc. (fka Avexis, Inc.) ranks #1136 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $120,016.16 across 39 transactions to 15 physicians and teaching hospitals - $3.1K per transaction and $8.0K per recipient on average.

Of the 3 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $69.5K across 3 transactions, 57.9% of the company's reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Novartis Gene Therapies, Inc. (fka Avexis, Inc.) made 3 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $69.5K, 57.9% of the company's reported total.

How Novartis Gene Therapies, Inc. (fka Avexis, Inc.) divides its payments

Ranked by total dollars reported per category

1. Compensation for Services…$69.5K2. Consulting Fee$1.9K3. Food and Beverage$749.72
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $69.5K 3
Consulting Fee $1.9K 2
Food and Beverage $749.72 10

Recipient Concentration in General Payments

The five largest recipient relationships account for $71,581.83 (99.2%) of $72,166.50 in this company's General Payments records across 13 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Novartis Gene Therapies, Inc. (fka Avexis, Inc.)

The five named recipients with the highest reported General Payments from this company

Univ Of Mi Hospitals & Hlth …$40.4KRonald Reagan Ucla$29.1KJerry Mendell$1.4KSaunder Bernes$565.00Ana Tesi Rocha$165.05
  1. 1

    Univ Of Mi Hospitals & Hlth Ctrs

    $40,397.44 across 2 reported transactions

  2. 2

    Ronald Reagan Ucla

    $29,078.34 across 1 reported transactions

  3. 3

    Jerry Mendell

    $1,376.00 across 1 reported transactions

  4. 4

    Saunder Bernes

    $565.00 across 1 reported transactions

  5. 5

    Ana Tesi Rocha

    $165.05 across 2 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $3.1K. Average per recipient: $8.0K.

Total Amount

$120,016.16

Avg per Transaction

$3.1K

Avg per Recipient

$8.0K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Novartis Gene Therapies, Inc. (fka Avexis, Inc.) Share

0.0%

#1136 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Novartis Gene Therapies, Inc. (fka Avexis, Inc.)

NuMED for Children, LLC

$120.0K 4 recipients

Aurobindo Pharma USA, Inc.

$120.1K 137 recipients

CorMedix Inc.

$120.2K 1,060 recipients

Shalby Advanced Technologies, Inc.

$120.5K 150 recipients

Ikon Spine LLC

$120.5K 15 recipients

Neptune Medical Inc.

$119.4K 49 recipients

Frequently Asked Questions

How much did Novartis Gene Therapies, Inc. (fka Avexis, Inc.) pay to physicians and hospitals in 2024? ▾
Novartis Gene Therapies, Inc. (fka Avexis, Inc.) made $120,016.16 in payments to physicians and hospitals in Program Year 2024, across 39 individual transactions. This represents 0.0% of all industry payments reported to CMS Open Payments.
How many physicians received payments from Novartis Gene Therapies, Inc. (fka Avexis, Inc.)? ▾
Averaging $8.0K per recipient, Novartis Gene Therapies, Inc. (fka Avexis, Inc.)'s 2024 payments reached 15 physicians and teaching hospitals.
What types of payments did Novartis Gene Therapies, Inc. (fka Avexis, Inc.) make? ▾
3 categories of general payment make up Novartis Gene Therapies, Inc. (fka Avexis, Inc.)'s reported activity, including consulting, meals, travel, and similar types. The largest general-payment category was "Compensation for Services Other Than Consulting" at $69.5K, representing 57.9% of the company's reported total.
How does Novartis Gene Therapies, Inc. (fka Avexis, Inc.) rank among pharmaceutical companies? ▾
By total payment amount, Novartis Gene Therapies, Inc. (fka Avexis, Inc.) sits at #1136 of 1,925 companies in the CMS Open Payments database for 2024.
What is the average payment size from Novartis Gene Therapies, Inc. (fka Avexis, Inc.)? ▾
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)'s 39 transactions to 15 recipients in 2024 averaged $3.1K per transaction.
Where does the payment data for Novartis Gene Therapies, Inc. (fka Avexis, Inc.) come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Novartis Gene Therapies, Inc. (fka Avexis, Inc.)'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.